Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + iberdomide + dexamethasone for relapsed or refractory t(11;14) multiple myeloma
ACTRN12622001158752Phase 2Recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Jul 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of venetoclax, iberdomide and dexamethasone in multiple myeloma (MM), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Very good partial response or better rate. Started Jul 2023; status: recruiting.
02
Drugs
venetoclaxiberdomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12622001158752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001158752.